Revolution Medicines, Inc. Operating Income Loss

• Revolution Medicines, Inc. showed a decrease of -71.5% in Operating Income Loss from 2024 to 2025.
• This data is from Revolution Medicines, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
• XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2018 to 2025), Revolution Medicines, Inc.'s Operating Income Loss has declined by 2,831.8%.
• Historical annual values: Fiscal year 2025: -$1.18 billion | Fiscal year 2024: -$689.52 million | Fiscal year 2023: -$487.19 million | Fiscal year 2022: -$258.28 million | Fiscal year 2021: -$188.01 million | Fiscal year 2020: -$110.70 million | Fiscal year 2019: -$54.12 million | Fiscal year 2018: -$40.33 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026